Please Wait...

Steve Goldstein

Translation skills

Main profile

Steve Goldstein
Director Study QC, IRT

Mr. Goldstein has over 20 years of regulated systems experience, which includes 13 focused on clinical IRT primarily for a clinical packaging and distribution vendor.  Mr. Goldstein brings a clinical supplies perspective to IRT systems that complements the clinical perspective employed on most IRT teams.  Mr. Goldstein joined BioClinica in 2009, and his current responsibilities include managing the Study QC team. He holds responsibility for study-specific testing, validation, and QC activities of BioClinica's EDC and IRT systems.  Mr. Goldstein received a B.A. in Chemistry from Cornell University and a M.S. in Chemical Engineering from Georgia Tech.

Blogs

With the increasing complexity in protocols and need to increase the cost-effectiveness of studies, your IRT-related decisions play an even greater role in ensuring the most appropriate patient randomization and clinical supply strategies. Gone are the days of being able to use the "tried and true" IRT systems without further consideration of if they meet your protocol requirements.

In the last blog we talked about how technology transfer is gaining ground on the conventional Software as a Service (SaaS) IRT sourcing model. In this blog post, I will explain the advantages of the technology and design behind Trident that make it particularly well-suited for IRT technology transfer. So let's dive right in.

When it comes to Interactive Response Technology (IRT) – systems used to perform subject randomization, drug dispensing and study drug resupply – Software as a Service (SaaS) continues to be the conventional delivery model including here at BioClinica.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

A great resource for Alzheimers's research teams. https://t.co/qhVP6ImwoO
bioclinica (18 hours ago)
RT @bioclinica: #Pharmacovigilance: Get up-to-speed on latest ind. trends & best practices + hear how others R meeting today's most pressin…
bioclinica (19 hours ago)
RT @Xtalks: Trends in #Pharmacovigilance – Market Research and Future Impact This webinar will discuss an overview of key findings within r…
bioclinica (19 hours ago)
RT @IntClinTrials: Patient loss and can reduced by introducing new methods during the follow-up period. Martin Collyer at @bioclinica tells…
bioclinica (19 hours ago)
@bioclinica experts talk candidly about #Alzheimer's research & where improvements can be made. Joyce Suhy, Marieke… https://t.co/u1Wmu41jRr
bioclinica (19 hours ago)
RT @ACROhealth: @MaryWolleyRA Mary Woolley @ResearchAmerica: 80% have heard of #clinicaltrials. 75% think trial participation is as importa…
bioclinica (1 week ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen